Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045760 · ClinicalTrials.gov registry record · Phase 4
The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00045760 is a Phase 4 study that has completed, run by Eli Lilly and Company.
The verdict
NCT00045760, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction. It usually results from bacterial infections, but it may occur in response to other pathogens, such as fungi, viruses, and parasites.
Interventions
- DRUG Drotrecogin alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045760
The ClinicalTrials.gov registry entry for NCT00045760 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drotrecogin alfa (activated) is the first listed.
NCT00045760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045760 about?
NCT00045760 is a clinical study titled "The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis". Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction. It usually results from bacterial infections, but it may occur in response to other pathogens, such as fungi, viruses, and parasites.
What is the current status of trial NCT00045760?
This trial is currently completed. It is a Phase 4 study. The study started on 2002-09.
What interventions are being tested in trial NCT00045760?
The interventions under investigation include: Drotrecogin alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT00045760?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.